ArticleStem cell research & therapy2016
Establishing a tree shrew model of systemic lupus erythematosus and cell transplantation treatment.
Article in Stem cell research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Integrated single cell and spatial transcriptomics reveals the cellular and molecular mechanisms underlying UCMSCs treatment of ovarian aging in tree shrews.Stem cell research & therapy · 2026Article
- Cross-sectional atlas of the tree shrew (Frontiers in veterinary science · 2026Article
- Tree shrews as a new animal model for systemic sclerosis research.Frontiers in immunology · 2024Article
- Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI Town Hall report.Stem cell research & therapy · 2023Article
- Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus.Archivum immunologiae et therapiae experimentalis · 2021Review
- The tree shrew as a model for infectious diseases research.Journal of thoracic disease · 2018Review
- Involvement of TLR3-Dependent PGES Expression in Immunosuppression by Human Bone Marrow Mesenchymal Stem Cells.Stem cell reviews and reports · 2018Article
- Immunomodulatory Effect of Tremella Polysaccharides against Cyclophosphamide-Induced Immunosuppression in Mice.Molecules (Basel, Switzerland) · 2018Article
- Tree shrew (Zoological research · 2017Review
- Age-related changes of corneal endothelial cell in healthy Chinese tree shrew measured by non-contact specular microscope.International journal of ophthalmology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe establishment of a tree shrew model for systemic lupus erythematosus (SLE) provides a new method to evaluate the pathogenesis of autoimmune diseases.
methodsEighty tree shrews were randomly divided into four groups receiving either an intraperitoneal injection of pristane, lipopolysaccharide (LPS), or pristane and LPS, or no injection. Three weeks after injection, the SLE model tree shrews were divided into the model group and the treatment group. Tree shrews in the treatment group and the normal control group were infused with umbilical cord mesenchymal stem cells (UC-MSCs). The cells were labeled with DiR. Two weeks after transplantation, three groups of tree shrews were analyzed for urine protein, serum antinuclear antibodies and antiphospholipid, and inflammatory cytokine antibody microarray detection. The heart, liver, spleen, lung, and kidney were collected from the three groups and subjected to hematoxylin and eosin (HE) staining and detection of renal immune complex deposition.
resultsHE staining indicated pathology in the model group. Red fluorescence revealed immune complex deposition in the kidneys from the model group.
conclusionsThe combined intraperitoneal injection of pristane and LPS is the best way to induce SLE pathological changes. The pathological changes improved after UC-MSC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.